These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

229 related items for PubMed ID: 19525224

  • 21. How gene polymorphisms can influence clinical response and toxicity following R-CHOP therapy in patients with diffuse large B cell lymphoma.
    Falduto A, Cimino F, Speciale A, Musolino C, Gangemi S, Saija A, Allegra A.
    Blood Rev; 2017 Jul; 31(4):235-249. PubMed ID: 28262268
    [Abstract] [Full Text] [Related]

  • 22. GAPDH Expression Predicts the Response to R-CHOP, the Tumor Metabolic Status, and the Response of DLBCL Patients to Metabolic Inhibitors.
    Chiche J, Reverso-Meinietti J, Mouchotte A, Rubio-Patiño C, Mhaidly R, Villa E, Bossowski JP, Proics E, Grima-Reyes M, Paquet A, Fragaki K, Marchetti S, Briere J, Ambrosetti D, Michiels JF, Molina TJ, Copie-Bergman C, Lehmann-Che J, Peyrottes I, Peyrade F, de Kerviler E, Taillan B, Garnier G, Verhoeyen E, Paquis-Flucklinger V, Shintu L, Delwail V, Delpech-Debiais C, Delarue R, Bosly A, Petrella T, Brisou G, Nadel B, Barbry P, Mounier N, Thieblemont C, Ricci JE.
    Cell Metab; 2019 Jun 04; 29(6):1243-1257.e10. PubMed ID: 30827861
    [Abstract] [Full Text] [Related]

  • 23. Young patients with non-germinal center B-cell-like diffuse large B-cell lymphoma benefit from intensified chemotherapy with ACVBP plus rituximab compared with CHOP plus rituximab: analysis of data from the Groupe d'Etudes des Lymphomes de l'Adulte/lymphoma study association phase III trial LNH 03-2B.
    Molina TJ, Canioni D, Copie-Bergman C, Recher C, Brière J, Haioun C, Berger F, Fermé C, Copin MC, Casasnovas O, Thieblemont C, Petrella T, Leroy K, Salles G, Fabiani B, Morschauser F, Mounier N, Coiffier B, Jardin F, Gaulard P, Jais JP, Tilly H.
    J Clin Oncol; 2014 Dec 10; 32(35):3996-4003. PubMed ID: 25385729
    [Abstract] [Full Text] [Related]

  • 24. High expression of AP2M1 correlates with worse prognosis by regulating immune microenvironment and drug resistance to R-CHOP in diffuse large B cell lymphoma.
    Liu X, Zhao X, Yang J, Wang H, Piao Y, Wang L.
    Eur J Haematol; 2023 Feb 10; 110(2):198-208. PubMed ID: 36335584
    [Abstract] [Full Text] [Related]

  • 25. Human leukocyte antigen-DR expression on flow cytometry and tumor-associated macrophages in diffuse large B-cell lymphoma treated by rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone therapy: retrospective cohort study.
    Yamamoto W, Nakamura N, Tomita N, Takeuchi K, Ishii Y, Takahashi H, Watanabe R, Takasaki H, Motomura S, Kobayashi S, Yokose T, Ishigatsubo Y, Sakai R.
    Leuk Lymphoma; 2014 Dec 10; 55(12):2721-7. PubMed ID: 24528218
    [Abstract] [Full Text] [Related]

  • 26. Thioredoxin-1 as a biological predictive marker for selecting diffuse large B-cell lymphoma patients for etoposide-containing treatment.
    Kari EJM, Kuusisto MEL, Honkavaara P, Hakalahti A, Haapasaari KM, Bloigu R, Karihtala P, Teppo HR, Pirinen R, Turpeenniemi-Hujanen T, Kuittinen O.
    Eur J Haematol; 2020 Aug 10; 105(2):156-163. PubMed ID: 32248578
    [Abstract] [Full Text] [Related]

  • 27. Combination of ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for treatment-naive patients with CD20-positive B-cell non-Hodgkin lymphoma: a non-randomised, phase 1b study.
    Younes A, Thieblemont C, Morschhauser F, Flinn I, Friedberg JW, Amorim S, Hivert B, Westin J, Vermeulen J, Bandyopadhyay N, de Vries R, Balasubramanian S, Hellemans P, Smit JW, Fourneau N, Oki Y.
    Lancet Oncol; 2014 Aug 10; 15(9):1019-26. PubMed ID: 25042202
    [Abstract] [Full Text] [Related]

  • 28. MicroRNA-21 regulates the sensitivity of diffuse large B-cell lymphoma cells to the CHOP chemotherapy regimen.
    Bai H, Wei J, Deng C, Yang X, Wang C, Xu R.
    Int J Hematol; 2013 Feb 10; 97(2):223-31. PubMed ID: 23275230
    [Abstract] [Full Text] [Related]

  • 29. Treatment of gastrointestinal diffuse large B cell lymphoma in China: a 10-year retrospective study of 114 cases.
    Li X, Shen W, Cao J, Wang J, Chen F, Wang C, Zou S, Shen B, Zhao R, Li J, Shen Z.
    Ann Hematol; 2012 Nov 10; 91(11):1721-9. PubMed ID: 22733613
    [Abstract] [Full Text] [Related]

  • 30. Lenalidomide combined with R-CHOP overcomes negative prognostic impact of non-germinal center B-cell phenotype in newly diagnosed diffuse large B-Cell lymphoma: a phase II study.
    Nowakowski GS, LaPlant B, Macon WR, Reeder CB, Foran JM, Nelson GD, Thompson CA, Rivera CE, Inwards DJ, Micallef IN, Johnston PB, Porrata LF, Ansell SM, Gascoyne RD, Habermann TM, Witzig TE.
    J Clin Oncol; 2015 Jan 20; 33(3):251-7. PubMed ID: 25135992
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. [Treatment approaches for diffuse large B-cell lymphoma].
    Miyazaki K, Yamaguchi M.
    Nihon Rinsho; 2014 Mar 20; 72(3):483-7. PubMed ID: 24724408
    [Abstract] [Full Text] [Related]

  • 34. CD47 Expression Defines Efficacy of Rituximab with CHOP in Non-Germinal Center B-cell (Non-GCB) Diffuse Large B-cell Lymphoma Patients (DLBCL), but Not in GCB DLBCL.
    Bouwstra R, He Y, de Boer J, Kooistra H, Cendrowicz E, Fehrmann RSN, Ammatuna E, Zu Eulenburg C, Nijland M, Huls G, Bremer E, van Meerten T.
    Cancer Immunol Res; 2019 Oct 20; 7(10):1663-1671. PubMed ID: 31409608
    [Abstract] [Full Text] [Related]

  • 35. Short-term efficacy of rituximab-CHOP and CHOP regimens on two subtypes of diffuse large B-cell lymphoma.
    Xia Y, Li ZM, Shi YX, Xia ZJ, Jiang WQ, Huang HQ.
    Ai Zheng; 2009 Feb 20; 28(2):146-9. PubMed ID: 19550126
    [Abstract] [Full Text] [Related]

  • 36. Prognostic importance of the soluble form of IL-2 receptorα (sIL-2Rα) and its relationship with surface expression of IL-2Rα (CD25) of lymphoma cells in diffuse large B-cell lymphoma treated with CHOP-like regimen with or without rituximab: a retrospective analysis of 338 cases.
    Hashimoto Y, Yokohama A, Saitoh A, Nakahashi H, Toyama K, Mitsui T, Koiso H, Saitoh T, Handa H, Uchiumi H, Jinbo T, Murayama K, Matsumoto M, Sawamura M, Karasawa M, Murakami H, Hirato J, Nojima Y, Kojima M, Tsukamoto N.
    J Clin Exp Hematop; 2013 Feb 20; 53(3):197-205. PubMed ID: 24369221
    [Abstract] [Full Text] [Related]

  • 37. R-split-CHOP chemotherapy for elderly patients with diffuse large B-cell lymphoma.
    Kreher S, Lammer F, Augustin D, Pezzutto A, Baldus CD.
    Eur J Haematol; 2014 Jul 20; 93(1):70-6. PubMed ID: 24612334
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. Everolimus combined with R-CHOP-21 for new, untreated, diffuse large B-cell lymphoma (NCCTG 1085 [Alliance]): safety and efficacy results of a phase 1 and feasibility trial.
    Johnston PB, LaPlant B, McPhail E, Habermann TM, Inwards DJ, Micallef IN, Colgan JP, Nowakowski GS, Ansell SM, Witzig TE.
    Lancet Haematol; 2016 Jul 20; 3(7):e309-16. PubMed ID: 27374464
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 12.